

the goal of developing a live, **attenuated RSV vaccine**, we have now attempted to further **attenuate** ts-1 NG-1 by mutagenesis with 5-FU and 5-azacytidine. Four mutants that are phenotypically different from the ts-1 NG-1 parental virus were identified. Each of the four mutants was more restricted in replication in BALB/c mice compared with the ts-1 NG-1 parental virus. One of the ts-1 NG-1 derivatives, termed A-20-4, which showed the lowest (35 degree C) in vitro shutoff temperature and which was also completely restricted in replication in BALB/c mice, was selected for further evaluation in seronegative chimpanzees. A-20-4 did not cause rhinorrhea in chimpanzees but induced detectable titers of serum **RSV** neutralizing antibodies in 2 of 4 chimpanzees. Apparent complete protection to subsequent challenge with wild-type **RSV** was observed in each of the four chimpanzees previously immunized with A-20-4. The ts-1 NG-1 A-20-4 mutant thus represents a promising live **attenuated RSV vaccine** candidate.

1995

**46/3,AB/9** (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

09749651 BIOSIS NO.: 199598204569

**Progress toward the development of a live attenuated respiratory syncytial virus (RSV) vaccine.**

AUTHOR: **Murphy Brian R** (a); Crowe James E Jr(a); Bui Phuong T(a); Elkins William R(a); Firestone Cai-Yen(a); Chanock Robert M(a); Lubeck Michael D; Karron Ruth; Clements Mary Lou; Wright Peter F; Siber George R

AUTHOR ADDRESS: (a)Natl. Inst. Health, NIAID, Bethesda, MD 20892-0702\*\*USA

JOURNAL: Journal of Cellular Biochemistry Supplement 0 (19A):p274 1995

CONFERENCE/MEETING: Keystone Symposium on Molecular Aspects of Viral Immunity Keystone, Colorado, USA January 16-23, 1995

ISSN: 0733-1959

RECORD TYPE: Citation

LANGUAGE: English

1995

**46/3,AB/10** (Item 9 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

09696672 BIOSIS NO.: 199598151590

**Live attenuated vaccines for respiratory syncytial virus and parainfluenza virus type 3.**

**BOOK TITLE: Strategies for pediatric vaccines: Conventional and molecular approaches**

AUTHOR: **Murphy Brian R** (a); Crowe James E Jr; Lubeck Michael D; Hsu Kuo-Hom Lee; Hall Susan L; Karron Ruth A; Clements Mary Lou; Wright Peter F; Belshe Robert B; Chanock Robert M

BOOK AUTHOR/EDITOR: Redfern D E: Ed

AUTHOR ADDRESS: (a)Respir. Viruses Sect., Lab. Infectious Diseases, National Inst. Allergy Infectious Diseases, Nat\*\*USA

p173-178 1994

BOOK PUBLISHER: Ross Products Division, Abbott Laboratories, 625 Cleveland Avenue, Columbus, Ohio 43216, USA

CONFERENCE/MEETING: 104th Ross Conference on Pediatric Research San Diego, California, USA September 18-21, 1993

RECORD TYPE: Citation

LANGUAGE: English

6, August 14, 2001, 15:50

Copied from 09444422 on 26-02-2004

1994

46/3,AB/11 (Item 10 from file: 5)  
 DIALOG(R) File 5: Biosis Previews(R)  
 (c) 2001 BIOSIS. All rts. reserv.

09400555 BIOSIS NO.: 199497408925

**A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.**

AUTHOR: Crowe James E Jr(a); Bui Phuong T; Davis Alan R; Chanock Robert M; Murphy Brian R

AUTHOR ADDRESS: (a) Respiratory Viruses Sect., Lab. Infectious Diseases, Natl. Inst. Allergy and Infectious Diseases\*\*USA

JOURNAL: Vaccine 12 (9):p783-790 1994

ISSN: 0264-410X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** A cold-passaged (cp), temperature-sensitive (ts) **RSV** mutant designated **RSV** cpts-248 (shut-off temperature 38 degree C), which possesses host-range mutations acquired during 52 passages at low temperature in bovine tissue culture and a ts phenotype introduced by subsequent chemical mutagenesis, was found previously to be **attenuated**, **immunogenic**, and protective against wild-type challenge in seronegative chimpanzees. We sought to introduce additional attenuating mutations such as small-plaque (sp) and ts mutations into **RSV** cpts-248 by chemical mutagenesis with 5-fluorouracil with the intent of obtaining cpts-248 derivatives that are more **attenuated** in mice or chimpanzees and that are more genetically stable following replication in vivo. Ten mutants of **RSV** cpts-248 which had acquired a sp phenotype or a second ts mutation were generated by chemical mutagenesis. Five cpts-248 derivatives which had acquired mutations that specified a 36 degree C shut-off temperature for plaque formation and one which had acquired only a sp phenotype were more restricted in replication in Balb/c mice than the cpts-248 parental strain. One mutant, designated **RSV** cpts-248/404 (shut-off temperature 36 degree C), was 100 times more restricted in replication in the nasal turbinates of mice and 1000 times more restricted in the nasopharynx of seronegative chimpanzees than its cpts-248 parent. The cpts-248/404 mutant was completely restricted in replication in the lower respiratory tract of chimpanzees even following direct intratracheal administration. The ts phenotype of the cpts-248/404 mutant was stable during replication in vivo in mice and chimpanzees. Chimpanzees immunized with cpts-248/404 were fully protected against upper respiratory tract disease and lower respiratory tract virus replication upon subsequent challenge with wild-type virus. The cpts-248/404 virus and related mutants exhibit many desirable characteristics which make them promising **vaccine** candidates.

1994

46/3,AB/12 (Item 11 from file: 5)  
 DIALOG(R) File 5: Biosis Previews(R)  
 (c) 2001 BIOSIS. All rts. reserv.

09355091 BIOSIS NO.: 199497363461

**Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by**

7, August 14, 2001, 15:50

Copied from 09444422 on 26-02-2004

**introduction of additional attenuating mutations during chemical mutagenesis.**

AUTHOR: Crowe James E Jr(a); Bui Phuong T; London William T; Davis Alan R; Hung Paul P; Chanock Robert M; **Murphy Brian R**  
 AUTHOR ADDRESS: (a)Respiratory Viruses Section, Lab. Infectious Diseases, Natl. Inst. Allergy Infectious Diseases, N\*\*USA  
 JOURNAL: Vaccine 12 (8):p691-699 1994  
 ISSN: 0264-410X  
 DOCUMENT TYPE: Article  
 RECORD TYPE: Abstract  
 LANGUAGE: English

ABSTRACT: A cold-passaged **RSV** mutant, designated cp-**RSV**, while acquired host range mutations during 52 passages at low temperature in bovine tissue culture, was completely **attenuated** for seropositive adults and children but retained the capacity to cause upper respiratory disease in seronegative infants. We sought to introduce additional attenuating mutations, such as temperature-sensitive (t) and small-plaque (sp) mutations, into the cp-**RSV** mutant, which is a ts + virus, in order to generate a mutant which would be satisfactorily **attenuated** in seronegative infants and young children. Nine mutants of cp-**RSV**, which had acquired either the ts or small-plaque sp phenotype, were generated by chemical mutagenesis with 5-fluorouracil. The two ts mutants with the lowest in vitro shut-off temperature, namely the cpts-248 (38 degree C) and cpts-530 (39 degree C) mutants, were the most restricted of the nine cp-**RSV** mutant progeny tested for efficiency of replication in Balb/c mice. In seronegative chimpanzees, the cpts-248 mutant replicated fourfold less efficiently in the nasopharynx and caused significantly less rhinorrhoea than its cp-**RSV** parent. The cpts-248 mutant virus, like its cp-**RSV** parent, was 1000-fold restricted in replication in the trachea compared with wild-type **RSV**. Previously, another candidate **RSV** live **attenuated vaccine** strain, a mutant designated ts-1, exhibited some instability of its ts phenotype following replication in susceptible humans or chimpanzees. Hence, we sought cp-**RSV** ts progeny that exhibited a greater degree of stability of the ts phenotype than the prototype ts-1 mutant. The cpts-248 and cpts-530 progeny viruses exhibited a greater degree of stability of the ts phenotype in nude mice than the ts-1 virus, and in chimpanzees, the former mutant also exhibited a greater stability of its ts phenotype than ts-1. The cpts-248 mutant was **immunogenic** and induced a high level of resistance in chimpanzees to subsequent challenge with wild-type **RSV**. The cpts-248 mutant therefore exhibits a set of properties that make it a promising **vaccine** candidate. These desirable properties of cpts-248 suggest that the mutant should be tested in humans for its suitability in immunoprophylaxis.

1994

46/3,AB/13 (Item 12 from file: 5)  
 DIALOG(R)File 5: Biosis Previews(R)  
 (c) 2001 BIOSIS. All rts. reserv.

09230715 BIOSIS NO.: 199497239085

**An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.**

AUTHOR: **Murphy Brian R** (a); Hall Susan L; Kulkarni Arun B; Crowe James E Jr; **Collins Peter L**; Connors Mark; Karron Ruth A; Chanock Robert M  
 AUTHOR ADDRESS: (a)Lab. Infect. Dis., Natl. Inst. Allergy Infect. Dis., Natl. Inst. Health, Bethesda, MD\*\*USA  
 JOURNAL: Virus Research 32 (1):p13-36 1994  
 ISSN: 0168-1702

8, August 14, 2001, 15:50

Copied from 09444422 on 26-02-2004

DOCUMENT TYPE: Literature Review  
 RECORD TYPE: Abstract  
 LANGUAGE: English

**ABSTRACT:** **RSV** and **PIV3** are responsible for about 30% of severe viral respiratory tract disease leading to hospitalization of infants and children. For this reason, there is a need to develop **vaccines** effective against these viruses. Since these viruses cause severe disease in early infancy, **vaccines** must be effective in the presence of maternal antibody. Currently, several strategies for immunization against these viruses are being explored including peptide **vaccines**, subunit **vaccines**, vectored **vaccines** (e.g., **vaccinia-RSV** or **adenovirus-RSV recombinants**), and live **attenuated** virus **vaccines**. The current status of these approaches is reviewed. In addition, the immunologic basis for the disease potentiation seen in vaccinees immunized with formalin-inactivated **RSV** during subsequent **RSV** infection is reviewed. The efficacy of immunization in the presence of maternal antibody is discussed. Much progress for a **RSV** and **PIV3 vaccine** has been made and successful immunization against each of these pathogens should be achieved within this decade.

1994

46/3,AB/14 (Item 13 from file: 5)  
 DIALOG(R) File 5: Biosis Previews(R)  
 (c) 2001 BIOSIS. All rts. reserv.

09081403 BIOSIS NO.: 199497089773

**A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.**

**AUTHOR:** Crowe James E Jr(a); Collins Peter L; London William T; Chanock Robert M; Murphy Brian R

**AUTHOR ADDRESS:** (a)Respiratory Viruses Section, Lab. Infectious Disease, Natl. Inst. Allergy Infectious Diseases, N\*\*USA

**JOURNAL:** Vaccine 11 (14):p1395-1404 1993

**ISSN:** 0264-410X

**DOCUMENT TYPE:** Article

**RECORD TYPE:** Abstract

**LANGUAGE:** English

**ABSTRACT:** **Respiratory syncytial virus (RSV)** is the most common cause of viral bronchiolitis and pneumonia in children. The present study compares the level of attenuation, genetic stability and efficacy of three conditional-lethal temperature-sensitive (ts) mutants of the **RSV A2** wild-type virus, designated ts-1, ts-1-NG1, and ts-4, in seronegative chimpanzees and also compares their efficacy with that of **vaccinia virus recombinants** that express the surface glycoproteins of **RSV**. Each of the ts mutants was highly **attenuated** in the lower respiratory tract, but still retained the capacity to induce significant rhinorrhoea. Each of the three ts mutants underwent partial reversion to a non-ts (ts+) phenotype during replication in a minority of the chimpanzees. The ts+ virus present in the upper respiratory tract of the chimpanzees did not spread to the lower respiratory tract and represented only a minority fraction of the virus present in the nasopharyngeal swab specimens. The ts mutants were highly **immunogenic** and provided resistance that effectively restricted **RSV** replication following virus challenge. In contrast, the **vaccinia-RSV recombinants** were less **immunogenic**. They protected the lungs of two of four chimpanzees challenged with **RSV**, but

failed to protect the upper respiratory tract. The chimpanzee can serve as a model for the rapid evaluation of further **attenuated** live **RSV vaccines** .

1993

**46/3,AB/30** (Item 29 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2001 BIOSIS. All rts. reserv.

06798795 BIOSIS NO.: 000088108234

**IMMUNOSUPPRESSION OF THE ANTIBODY RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS RSV BY PREEEXISTING SERUM ANTIBODIES PARTIAL PREVENTION BY TOPICAL INFECTION OF THE RESPIRATORY TRACT WITH VACCINIA VIRUS- RSV RECOMBINANTS**

AUTHOR: **MURPHY B R ; COLLINS P L ; LAWRENCE L ; ZUBAK J ; CHANOCK R M ; PRINCE G A**

AUTHOR ADDRESS: LAB. INFECT. DIS., NATL. INST. ALLERGY INFECT. DIS., NATL. INST. HEALTH, BETHESDA, MD. 20892.

JOURNAL: J GEN VIROL 70 (8). 1989. 2185-2190. 1989

FULL JOURNAL NAME: Journal of General Virology

CODEN: JGVIA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Immunization strategies to prevent **respiratory syncytial virus (RSV)** disease will involve immunization of infants less than 2 months of age who possess maternally derived **RSV** antibodies. **Vaccinia-RSV recombinant** viruses are useful tools for defining parameters important in immunization against **RSV** and also are being considered as live virus **vaccines** for use in humans. Previous studies demonstrated that passively acquired **RSV** antibodies can suppress the immune response and the protective efficacy of **vaccinia-RSV recombinants** administered by the intradermal route. The present study demonstrates that the suppressive effects of passively acquired antibody on immunity induced by intradermally administered **vaccinia-RSV recombinants** in cotton rats can be partially overcome by administration of the **recombinants** by the intranasal route.

1989

**46/3,AB/32** (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2001 Elsevier Science B.V. All rts. reserv.

06078131 EMBASE No: 1995108615

**Isolation anti characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus**

Hsu K.-H.L.; Crowe Jr. J.E.; Lubeck M.D.; Davis A.R.; Hung P.P.; Chanock R.M.; **Murphy B.R.**

Wyeth-Ayerst Research, P.O. Box 8299, Philadelphia, PA 19101 United States

Vaccine ( VACCINE ) (United Kingdom) 1995, 13/5 (509-515)

CODEN: VACCD ISSN: 0264-410X

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Ts-1, a temperature sensitive (ts) mutant of **RSV** , was previously

derived from RSV A2 virus by mutagenesis with 5-fluorouracil (5-FU). Ts-1 was **attenuated** for adult volunteers and seropositive children but retained a low level of virulence in seronegative infant vaccinees as indicated by the occurrence of upper respiratory tract disease. Ts-1 NG-1, a more defective derivative of ts-1, was produced by mutagenesis of ts-1 with nitrosoguanidine. However, ts-1 NG-1 still retained a low level of virulence for the upper respiratory tract and showed some genetic instability in chimpanzees. With renewed interest in the goal of developing a live, **attenuated RSV vaccine**, we have now attempted to further **attenuate** ts-1 NG-1 by mutagenesis with 5-FU and 5-azacytidine. Four mutants that are phenotypically different from the ts-1 NG-1 parental virus were identified. Each of the four mutants was more restricted in replication in BALB/c mice compared with the ts-1 NG-1 parental virus. One of the ts-1 NG-1 derivatives, termed A-20-4, which showed the lowest (35degreeC) in vitro shutoff temperature and which was also completely restricted in replication in BALB/c mice, was selected for further evaluation in seronegative chimpanzees. A-20-4 did not cause rhinorrhea in chimpanzees but induced detectable titers of serum **RSV** neutralizing antibodies in 2 of 4 chimpanzees. Apparent complete protection to subsequent challenge with wild-type **RSV** was observed in each of the four chimpanzees previously immunized with A-20-4. The ts-1 NG-1 A-20-4 mutant thus represents a promising live **attenuated RSV vaccine** candidate.

46/3,AB/40 (Item 9 from file: 73)  
 DIALOG(R) File 73:EMBASE  
 (c) 2001 Elsevier Science B.V. All rts. reserv.

03737603 EMBASE No: 1988187039

**Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses**

Murphy B.R. ; Prince G.A.; Collins P.L. ; Van Wyke Coelingh K.; Olmsted R.A.; Spriggs M.K.; Parrott R.H.; Kim H.-W.; Brandt C.D.; Chanock R.M.  
 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 United States  
 Virus Research ( VIRUS RES. ) (Netherlands) 1988, 11/1 (1-15)  
 CODEN: VIRED ISSN: 0168-1702  
 DOCUMENT TYPE: Journal  
 LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

**Vaccines** against parainfluenza (PIV) and respiratory syncytial viruses (**RSV**) that are currently being developed include both live and subunit **vaccines**. Candidate live PIV **vaccines** that have been found to be **attenuated** and efficacious in rodents or primate models are (1) cold-adapted, temperature-sensitive mutants of PIV-type 3 that have been serially passaged at low temperature (20degreeC) in simian kidney tissue culture; (2) protease-activation mutants (PIV-1-Sendai), which have mutations that decrease the cleavability of their F glycoprotein by host cell protease; (3) an animal virus, bovine PIV-3 virus, which is antigenically related to the human PIV-3 virus, and (4) **vaccinia recombinant** viruses bearing **RSV** or PIV-3 glycoproteins. Subunit **RSV** and PIV-3 viruses are being produced and evaluated as immunogens. A major concern with these **vaccines** is the possibility of disease potentiation following virus infection as occurred previously with formalin-inactivated measles and **RSV vaccines**. Studies indicate that PIV-3 and **RSV glycoprotein vaccines** are **immunogenic** and efficacious in animals but insufficient data exist to estimate their capacity to potentiate disease. However, since a cotton rat model is available to detect potentiated disease resulting from infection of cotton rats previously immunized with formalin-inactivated **RSV vaccine**, it is now possible to systematically

evaluate new **vaccines** in experimental animals for disease potentiation before studies are initiated in humans. It is likely within the next several years that one or more of these PIV or **RSV vaccines** will be tested in humans for safety and immunogenicity.

**46/3,AB/52 (Item 3 from file: 357)**

DIALOG(R)File 357:Derwent Biotechnology Abs

(c) 2001 Derwent Publ Ltd. All rts. reserv.

0127688 DBA Accession No.: 92-00180

**Rescue of synthetic analogs of respiratory- syncytial virus genomic RNA and effect of truncations and mutations on the expression of foreign reporter gene- potential application in recombinant vaccine development**

**AUTHOR: Collins P L ; Mink M A; Stec D S**

**CORPORATE SOURCE: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 7, Room 100, Bethesda, MD 20892, USA.**

**JOURNAL: Proc.Natl.Acad.Sci.U.S.A. (88, 21, 9663-67) 1991**

**CODEN: PNASA6**

**LANGUAGE: English**

**ABSTRACT:** The production of live **respiratory -syncytial virus (RSV)** from cDNA (which requires complementation by viral proteins) would provide a means for characterizing and producing **attenuated vaccine strains**. Towards this end, a cDNA was constructed which encoded **RSV -CAT**, an **RSV** viral RNA (vRNA) analog in which all of the viral translational open reading frames were deleted and replaced with the coding region of the bacterial chloramphenicol-acetyltransferase (CAT, EC-2.3.1.28) gene as a reporter for expression. **RSV -CAT** vRNA was synthesized in vitro from HgaI-linearized cDNA and transfected into **RSV -infected 293 cells**. The synthetic chimeric vRNAs were amplified, expressed and incorporated into virions. Amplification, expression and packaging were efficiently effected by a synthetic vRNA, **RSV -Shorter**, which contained only 105 nucleotides (nt) of the 15,222-nt **RSV** vRNA. The 105 nt of **RSV -Shorter** included (at the 3' end) the complete 44-nt leader region and adjacent 9-nt 1C gene start signal, and (at the 5' end) the 12-nt L-gene end signal fused to the last 40-nt of the 5' trailer region. (19 ref)

?

60/3,AB/1 (Item 1 from file: 348)  
 DIALOG(R) File 348:EUROPEAN PATENTS  
 (c) 2001 European Patent Office. All rts. reserv.

00334126

**CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF THE  
 GLYCOPROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS.  
 CHIMARENGLYKOPROTEINE, ENTHALTEND IMMUNOGENE SEGMENTE DES HUMANEN  
 RESPIRATORISCHEN SYNZYTIALVIRUS.  
 GLYCOPROTEINES CHIMERIQUES CONTENANT DES SEGMENTS IMMUNOGENIQUES DES  
 GLYCOPROTEINES DU VIRUS SYNCYTIAL RESPIRATOIRE HUMAIN.**

PATENT ASSIGNEE:

THE UPJOHN COMPANY, (230490), 301 Henrietta Street, Kalamazoo, Michigan  
 49001, (US), (applicant designated states:  
 AT;BE;CH;DE;FR;GB;IT;LI;LU;NL;SE)

INVENTOR:

WATHEN, Michael, 3183 St. Anthony Drive, Portage, MI 49002, (US)

LEGAL REPRESENTATIVE:

Perry, Robert Edward et al (41331), GILL JENNINGS & EVERY, Broadgate  
 House, 7 Eldon Street, London EC2M 7LH, (GB)

PATENT (CC, No, Kind, Date): EP 396563 A1 901114 (Basic)  
 EP 396563 B1 930210  
 WO 8905823 890629

APPLICATION (CC, No, Date): EP 88909879 881031; WO 88US3784 881031

PRIORITY (CC, No, Date): US 137387 871223

DESIGNATED STATES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

INTERNATIONAL PATENT CLASS: C07K-013/00; C12N-015/00; A61K-039/155;  
 C12N-007/00; C12N-001/20; C12N-001/18; C12N-005/00;

NOTE:

No A-document published by EPO

LANGUAGE (Publication,Procedural,Application): English; English; English  
 FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	EPBBF1	291
CLAIMS B	(German)	EPBBF1	234
CLAIMS B	(French)	EPBBF1	322
SPEC B	(English)	EPBBF1	11633
Total word count - document A			0
Total word count - document B			12480
Total word count - documents A + B			12480

60/3,AB/2 (Item 1 from file: 349)  
 DIALOG(R) File 349:PCT Fulltext  
 (c) 2001 WIPO/MicroPat. All rts. reserv.

00246794

**CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF THE  
 GLYCOPROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS  
 GLYCOPROTEINES CHIMERIQUES CONTENANT DES SEGMENTS IMMUNOGENIQUES DES  
 GLYCOPROTEINES DU VIRUS SYNCYTIAL RESPIRATOIRE HUMAIN**

Patent Applicant/Assignee:

THE UPJOHN COMPANY  
 WATHEN Michael

Inventor(s):

WATHEN Michael

Patent and Priority Information (Country, Number, Date):

Patent: WO 8905823 A1 19890629

Application: WO 88US3784 19881031 (PCT/WO US8803784)

Priority Application: US 87137387 19871223

Designated States: AT AU BE CH DE DK FI FR GB IT JP KR LU NL NO SE US

1, August 14, 2001, 16:14

Copied from 09444422 on 26-02-2004



Publication Language: English  
Fulltext Word Count: 15684

## English Abstract

This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human **respiratory syncytial virus**. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, **vaccines** made from the glycoproteins and methods for protecting humans by inoculation with said **vaccines** are also part of this invention.

## Japanese Abstract

Cette invention concerne des compositions d'ADN codant de nouvelles glycoprotéines chimeriques qui sont utiles pour la preparation de reponses immunes specifiques contre le virus syncytial respiratoire humain. Les compositions d'ADN comprennent des genes structuraux codant pour les glycoprotéines et des plasmides d'expression et de replication contenant les genes structuraux. Des cellules hotes transformees avec les compositions d'ADN decrites ci-dessus, des vaccins obtenus a partir des glycoprotéines ainsi que des procedes de protection des etres humains par inoculation desdits vaccins sont egalement decrits dans la presente invention.

60/3,AB/3 (Item 2 from file: 349)  
DIALOG(R) File 349:PCT Fulltext  
(c) 2001 WIPO/MicroPat. All rts. reserv.

00244169

RESPIRATORY SYNCYTIAL VIRUS: VACCINES AND DIAGNOSTIC ASSAYS  
**VIRUS SYNCYTIAL RESPIRATOIRE: VACCINS ET DOSAGES DE DIAGNOSTIC**

Patent Applicant/Assignee:

PRAXIS BIOLOGICS INC

Inventor(s):

PARADISO Peter R

HILDRETH Stephen W

HU Branda T

MARTIN-GALLARDO Antonia

ARUMUGHAM Rasappa

Patent and Priority Information (Country, Number, Date):

Patent: WO 8902935 A1 19890406

Application: WO 88US3399 19880929 (PCT/WO US8803399)

Priority Application: US 87102180 19870929; US 88247017 19880920

Designated States: AT AU BE CH DE DK FR GB IT JP KR LU NL SE

Publication Language: English

Fulltext Word Count: 22085

## English Abstract

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and **vaccines** against human **Respiratory Syncytial Virus** are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the **Respiratory Syncytial Virus** fusion protein or a neutralizing epitope of the G protein.

## Japanese Abstract

Sont decrits des polypeptides, des nucleotides, et des compositions utiles pour preparer des reactifs de diagnostic du Virus Syncytial Respiratoire Humain et des vaccins contre ce dernier. Les polypeptides

2, August 14, 2001, 16:14

Copied from 09444422 on 26-02-2004

comprennent des polypeptides courts se rapportant a un epitope de neutralisation et de fusion de la proteine de fusion du Virus Syncytial Respiratoire ou a un epitope de neutralisation de la proteine G.

**60/3,AB/5 (Item 2 from file: 654)**  
 DIALOG(R)File 654:US PAT.FULL.  
 (c) format only 2001 The Dialog Corp. All rts. reserv.

02272861

Utility  
 EXPRESSION SYSTEM FOR **RSV** GLYCOPROTEIN F AND G  
 [ For preparing specific immune responses against human respiratory syncytial virus]

PATENT NO.: 5,288,630  
 ISSUED: February 22, 1994 (19940222)  
 INVENTOR(s): Wathen, Michael W., Portage, MI (Michigan), US (United States of America)  
 ASSIGNEE(s): The Upjohn Company, (A U.S. Company or Corporation ), Kalamazoo, MI (Michigan), US (United States of America)  
 [Assignee Code(s): 87912]  
 APPL. NO.: 7-979,505  
 FILED: November 20, 1992 (19921120)

#### CROSS-REFERENCE TO RELATED APPLICATIONS

This Application is a divisional of U.S. Ser. No. 07-543,780, filed Jun. 20, 1990, now U.S. Pat. No. 5,194,595, which is a continuation of International Application PCT-US88-037, filed Oct. 31, 1988, which was a continuation of U.S. Ser. No. 07-137,387, filed Dec. 23, 1987, abandoned.

FULL TEXT: 1290 lines

#### ABSTRACT

This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human **respiratory syncytial virus**. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, **vaccines** made from the glycoproteins and methods for protecting humans by inoculation with said **vaccines** are also part of this invention.

**60/3,AB/6 (Item 3 from file: 654)**  
 DIALOG(R)File 654:US PAT.FULL.  
 (c) format only 2001 The Dialog Corp. All rts. reserv.

02197487

Utility  
**RESPIRATORY SYNCYTIAL VIRUS : VACCINES**  
 [Polypeptide]

PATENT NO.: 5,223,254  
 ISSUED: June 29, 1993 (19930629)  
 INVENTOR(s): Paradiso, Peter R., Pittsford, NY (New York), US (United States of America)  
 Hildreth, Stephen W., Rochester, NY (New York), US (United States of America)

3, August 14, 2001, 16:14

Copied from 09444422 on 26-02-2004

States of America)  
 Hu, Branda T., Pittsford, NY (New York), US (United States of America)  
 Martin-Gallardo, Antonia, Pittsford, NY (New York), US (United States of America)  
 Arumugham, Rasappa, West Henrietta, NY (New York), US (United States of America)  
 ASSIGNEE(s): Praxis Biologics, Inc , (A U.S. Company or Corporation ),  
 Rochester, NY (New York), US (United States of America)  
 [Assignee Code(s): 20015]  
 EXTRA INFO: Assignment transaction [Reassigned], recorded June 11,  
 1997 (19970611)  
 APPL. NO.: 7-247,017  
 FILED: September 20, 1988 (19880920)

## CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of application Ser. No. 07-102,180, filed Sep. 29, 1987, currently abandoned.

FULL TEXT: 2397 lines

## ABSTRACT

Polypeptides, nucleotides, and compositions useful for preparing diagnostic reagents for and **vaccines** against human **Respiratory Syncytial Virus** are disclosed. The polypeptides include short polypeptides which are related to a neutralizing and fusion epitope of the **Respiratory Syncytial Virus** fusion protein or a neutralizing epitope of the G protein.

60/3,AB/7 (Item 4 from file: 654)  
 DIALOG(R) File 654:US PAT.FULL.  
 (c) format only 2001 The Dialog Corp. All rts. reserv.

02165840

## Utility

CHIMERIC GLYCOPROTEINS CONTAINING **IMMUNOGENIC** SEGMENTS OF THE  
 GLYCOPROTEINS OF HUMAN **RESPIRATORY SYNCYTIAL VIRUS**  
 [**Vaccines** for protecting humans by inoculation against respiratory system  
 infections]

PATENT NO.: 5,194,595  
 ISSUED: March 16, 1993 (19930316)  
 INVENTOR(s): Wathen, Michael W., Portage, MI (Michigan), US (United States of America)  
 ASSIGNEE(s): The Upjohn Company, (A U.S. Company or Corporation ),  
 Kalamazoo, MI (Michigan), US (United States of America)  
 [Assignee Code(s): 87912]  
 EXTRA INFO: Assignment transaction [Reassigned], recorded August 28,  
 1998 (19980828)  
 APPL. NO.: 7-543,780  
 FILED: June 20, 1990 (19900620)  
 PCT: PCT-US89-03784 (WO 89US3784)  
 Section 371 Date: June 20, 1990 (19900620)  
 Section 102(e) Date: June 20, 1990 (19900620)  
 Filing Date: October 31, 1988 (19881031)  
 Publication Number: WO87-04185 (WO 874185)  
 Publication Date: July 16, 1987 (19870716)

4, August 14, 2001, 16:14

Copied from 09444422 on 26-02-2004

This is a continuation-in-part of application Ser. No. 07-137,387, filed Dec. 23, 1987, now abandoned.

FULL TEXT: 1209 lines

#### ABSTRACT

This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human **respiratory syncytial virus**. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, **vaccines** made from the glycoproteins and methods for protecting humans by inoculation with said **vaccines** are also part of this invention.  
?